

Patent claims

1. A synergistic composition comprising a mixture of at least two benzoic acid derivatives selected from

2-acetoxybenzoic acid (acetylsalicylic acid)

2-hydroxybenzoic acid

2-methoxybenzoic acid

2,4-dihydroxybenzoic acid

2,4-diacetoxybenzoic acid

2-hydroxy-4-aminobenzoic acid

2,4-dimethoxybenzoic acid

2,6-dihydroxybenzoic acid

2,6-dimethoxybenzoic acid

2,3,4-trimethoxybenzoic acid

2,4,6-trihydroxybenzoic acid

2,4,6-trimethoxybenzoic acid

5-(2,4-difluoro-phenyl)salicylic acid

α -cyano-3-hydroxycinnamic acid

α -cyano-4-hydroxycinnamic acid

α -fluorocinnamic acid

α -methylcinnamic acid and

α -acetamidocinnamic acid.

2. A synergistic composition according to claim 1, characterized in that it comprises a synergistic mixture of

2,6-dihydroxy and 2-hydroxy-4-aminobenzoic acid,

2,6-dihydroxy and 2-acetoxybenzoic acid (acetylsalicylic acid),

2,6-dihydroxy and 2,4-diacetoxybenzoic acid,

2,6-dihydroxy and 2,4-dimethoxybenzoic acid,

2-hydroxy-4-amino- and 2-acetoxybenzoic acid (acetylsalicylic acid),

2-hydroxy-4-amino- and 2,4-dimethoxybenzoic acid,

2,4-dimethoxy- and 2-acetoxybenzoic acid,

2,4,6-trihydroxy- and 2,4-dimethoxybenzoic acid,
 2,4,6-trihydroxy- and 2,6-dihydroxybenzoic acid,
 2,4,6-trimethoxy- and 2,6-dihydroxybenzoic acid,
 2,4,6-trimethoxy- and 2-hydroxy-4-aminobenzoic acid,
 2,4,6-trimethoxy- and 2,4,6-trihydroxybenzoic acid or of
 2,4,6-trimethoxy- and 2,4-dimethoxybenzoic acid.

3. A synergistic composition according to claim 1, characterized in that it comprises a synergistic mixture of

2-hydroxy-4-aminobenzoic acid and 5-(2,4-difluorophenyl)-salicylic acid,
 2-acetoxybenzoic acid and 5-(2,4-difluorophenyl)salicylic acid,
 2-acetoxybenzoic acid and α -cyano-3-hydroxycinnamic acid,
 5-(2,4-difluorophenyl)salicylic acid and α -cyano-3-hydroxycinnamic acid,
 2-hydroxy-4-aminobenzoic acid and α -cyano-3-hydroxycinnamic acid,
 2-hydroxy-4-aminobenzoic acid and 2-acetoxybenzoic acid and 5-(2,4-difluorophenyl)salicylic acid,
 2-hydroxy-4-aminobenzoic acid and 2-acetoxybenzoic acid and α -cyano-3-hydroxycinnamic acid,
 2-hydroxy-4-aminobenzoic acid and 5-(2,4-difluorophenyl)-salicylic acid and α -cyano-3-hydroxycinnamic acid or of
 2-acetoxybenzoic acid and 5-(2,4-difluorophenyl)salicylic acid and α -cyano-3-hydroxycinnamic acid.

4. The composition as claimed in claim 1 comprising 2-hydroxy-4-aminobenzoic acid as a mixture with 2,4-dimethoxybenzoic acid.

5. The composition as claimed in claim 1 comprising 2,6-dihydroxybenzoic acid as a mixture with acetylsalicylic acid.

6. The composition as claimed in claim 1 comprising 2-hydroxy-4-aminobenzoic acid as a mixture with acetylsalicylic acid.

7. The composition as claimed in claim 1 comprising 2-hydroxy-4-aminobenzoic acid as a mixture with 2,6-dihydroxybenzoic acid.

8. The composition as claimed in claim 1 comprising 2,6-dihydroxybenzoic acid as a mixture with 2,4-dimethoxybenzoic acid.

9. The composition as claimed in one of claims 1 to 8 for use as a medicament.

10. The composition as claimed in one of claims 1 to 8 for use as an antitumor agent.

11. The medicament comprising a composition as claimed in one of claims 1 to 8 and a pharmaceutically tolerable inert pharmaceutical excipient.

12. The medicament as claimed in claim 11, characterized in that it comprises the active agents in a ratio of 1:9 to 9:1, preferably in a ratio of 2:1 to 1:2 and most preferably in a ratio of 1:1.

13. The medicament as claimed in claim 11 or 12, characterized in that it additionally comprises glucose.

14. The use of a composition as claimed in one of claims 1 to 8 for the preparation of a medicament for the treatment of carcinomatous disorders.

15. A pharmaceutical pack consisting of two medicaments each comprising at least one benzoic acid derivative selected from

2-acetoxybenzoic acid (acetylsalicylic acid)
2-hydroxybenzoic acid
2-methoxybenzoic acid
2,4-dihydroxybenzoic acid
2,4-diacetoxybenzoic acid
2-hydroxy-4-aminobenzoic acid
2,4-dimethoxybenzoic acid
2,6-dihydroxybenzoic acid
2,6-dimethoxybenzoic acid
2,3,4-trimethoxybenzoic acid
2,4,6-trihydroxybenzoic acid
2,4,6-trimethoxybenzoic acid
5-(2,4-difluoro-phenyl)salicylic acid
 α -cyano-3-hydroxycinnamic acid
 α -cyano-4-hydroxycinnamic acid
 α -fluorocinnamic acid
 α -methylcinnamic acid and
 α -acetamidocinnamic acid

for joined or timely shifted administration, wherein the pharmaceutical pack comprises at least two different benzoic acid derivatives.

16. A pharmaceutical pack according to claim 15, characterized in that the two medicaments are provided in different packages, wherein on the package insert of one medicament and/or on the package insert of the other medicament it is pointed to the joined or timely shifted administration of the medicaments.

17. Composition comprising 5-(2,4-difluorophenyl)salicylic acid and at least one other salicylic acid derivative.

18. Composition according to claim 17 wherein the at least one other salicylic acid derivative is selected from the group consisting of

2-acetoxybenzoic acid (acetylsalicylic acid)
2-hydroxybenzoic acid
2-methoxybenzoic acid
2,4-dihydroxybenzoic acid
2,4-diacetoxybenzoic acid
2-hydroxy-4-aminobenzoic acid
2,4-dimethoxybenzoic acid
2,6-dihydroxybenzoic acid
2,6-dimethoxybenzoic acid
2,3,4-trimethoxybenzoic acid
2,4,6-trihydroxybenzoic acid
2,4,6-trimethoxybenzoic acid
salicylic acid.

19. Composition according to claim 18 wherein the salicylic acid derivative is selected from the group consisting of

2-hydroxy-4-aminobenzoic acid,
2-acetoxybenzoic acid,
salicylic acid,
2,6-dihydroxybenzoic acid and
2,4,6-trihydroxybenzoic acid.

20. Composition according to claim 17 comprising 5-(2,4-difluorophenyl)salicylic acid in combination with 2-hydroxy-4-aminobenzoic acid.

21. Composition according to claim 17 comprising 5-(2,4-difluorophenyl)salicylic acid in combination with 2-acetoxybenzoic acid.

22. Composition according to claim 17 comprising 5-(2,4-difluorophenyl)salicylic acid in combination with 2,6-dihydroxybenzoic acid.

23. Composition according to claim 17 comprising 5-(2,4-difluorophenyl)salicylic acid in combination with 2,4,6-trihydroxybenzoic acid.

24. Composition according to claim 17 comprising 5-(2,4-difluorophenyl)salicylic acid in combination with acetylsalicylic acid and 2-hydroxy-4-aminobenzoic acid.

25. Medicament comprising a composition as claimed in claim 17 and a pharmaceutically tolerable excipient.

26. Medicament comprising a composition as claimed in claim 18 and a pharmaceutically tolerable excipient.

27. Medicament comprising a composition as claimed in claim 19 and a pharmaceutically tolerable excipient.

28. Medicament comprising a composition as claimed in claim 20 and a pharmaceutically tolerable excipient.

29. Medicament comprising a composition as claimed in claim 21 and a pharmaceutically tolerable excipient.

30. Medicament comprising a composition as claimed in claim 22 and a pharmaceutically tolerable excipient.

31. Medicament comprising a composition as claimed in claim 23 and a pharmaceutically tolerable excipient.

32. Medicament comprising a composition as claimed in claim 24 and a pharmaceutically tolerable excipient.

33. Pharmaceutical pack consisting of two medicaments wherein one medicament comprises 5-(2,4-difluoro-phenyl)salicylic acid and the other medicament comprises at least one other salicylic acid derivative for joint or timely shifted administration.

34. Pharmaceutical pack according to claim 33 wherein the at least one other salicylic acid derivative is selected from the group consisting of

2-acetoxybenzoic acid (acetylsalicylic acid)
2-hydroxybenzoic acid
2-methoxybenzoic acid
2,4-dihydroxybenzoic acid
2,4-diacetoxybenzoic acid
2-hydroxy-4-aminobenzoic acid
2,4-dimethoxybenzoic acid
2,6-dihydroxybenzoic acid
2,6-dimethoxybenzoic acid
2,3,4-trimethoxybenzoic acid
2,4,6-trihydroxybenzoic acid
2,4,6-trimethoxybenzoic acid
salicylic acid.

35. Pharmaceutical pack according to claim 33 wherein the at least one other salicylic acid derivative is selected from the group consisting of

2-hydroxy-4-aminobenzoic acid,
2-acetoxybenzoic acid,
salicylic acid,
2,6-dihydroxybenzoic acid and
2,4,6-trihydroxybenzoic acid.

36. Pharmaceutical pack according to claim 33 wherein the at least one other salicylic acid derivative is 2-hydroxy-4-aminobenzoic acid.

37. Pharmaceutical pack according to claim 33 wherein the at least one other salicylic acid derivative is 2-acetoxybenzoic acid.

38. Pharmaceutical pack according to claim 33 wherein the at least one other salicylic acid derivative is 2,6-dihydroxybenzoic acid.

39. Pharmaceutical pack according to claim 33 wherein the at least one other salicylic acid derivative is 2,4,6-trihydroxybenzoic acid.

40. Pharmaceutical pack according to claim 33 wherein the other medicament contains a combination of acetylsalicylic acid and 2-hydroxy-4-aminobenzoic acid.

41. Method of treating cancer wherein a composition of claim 17 is administered to a patient in need of such a treatment.

42. Method of treating cancer wherein a composition of claim 18 is administered to a patient in need of such a treatment.

43. Method of treating cancer wherein a composition of claim 19 is administered to a patient in need of such a treatment.

44. Method of treating cancer wherein a composition of claim 20 is administered to a patient in need of such a treatment.

45. Method of treating cancer wherein a composition of claim 21 is administered to a patient in need of such a treatment.

46. Method of treating cancer wherein a composition of claim 22 is administered to a patient in need of such a treatment.

47. Method of treating cancer wherein a composition of claim 23 is administered to a patient in need of such a treatment.

48. Method of treating cancer wherein a composition of claim 24 is administered to a patient in need of such a treatment.